RESUMEN
The bcl-2 protein plays a role in the regulation of programmed cell death (PCD), overriding apoptosis. Its expression has been reported in breast ductal cells, where it is believed to be involved in the hormonal regulation of hyperplasia and involution. To date, bcl-2 gene product has not been investigated on breast cancer FNA. The expression of bcl-2 protein was evaluated using an immunoalkaline phosphatase technique in 54 pre-operative breast cancer aspirates and in paraffin-embedded sections from 20 matched surgical specimens. A high rate of bcl-2 protein expression was found on FNA samples (65%) and on the corresponding tissue sections (60%); there was a nearly absolute concordance in the two specimens, with 19/20 (95%) cases showing a concordant staining. These findings concur with the view that bcl-2 gene is frequently expressed in breast cancer, possibly through a hormonal-dependent pathway.
Asunto(s)
Neoplasias de la Mama/metabolismo , Proteínas Proto-Oncogénicas/biosíntesis , Apoptosis/genética , Biopsia con Aguja , Neoplasias de la Mama/patología , Femenino , Expresión Génica , Humanos , Inmunohistoquímica , Adhesión en Parafina , Proteínas Proto-Oncogénicas/genética , Proteínas Proto-Oncogénicas c-bcl-2 , Estudios RetrospectivosRESUMEN
The authors studied the effect of different therapeutical regimens on the growth of children suffering from asthma. These patients were subdivided into four groups of ten patients according to their therapeutic regimens: Group A = ketotifene (1 mg, two times/day), Group B = diproprionate beclomethasone + salbuthamol (100 + 200 mcg, 3 times/day), Group C = ketotifene + diproprionate beclomethasone, Group D = disodiumcromoglycate (20 mg, 3 times/day). The patients were followed for at least 1 year. Our study has shown that all the children treated with the four different regimens had a normal growth and growth velocity.